Biora Therapeutics, Inc. (NASDAQ:BIOR) Short Interest Update

Biora Therapeutics, Inc. (NASDAQ:BIOR) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 258,100 shares, an increase of 27.9% from the October 31st total of 201,800 shares. Based on an average daily trading volume, of 68,700 shares, the short-interest ratio is currently 3.8 days. Approximately 5.9% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their target price on shares of Biora Therapeutics from $15.00 to $23.00 and gave the stock a “buy” rating in a research report on Monday, November 18th.

Biora Therapeutics Stock Performance

NASDAQ:BIOR traded up $0.07 on Monday, hitting $2.02. The stock had a trading volume of 119,385 shares, compared to its average volume of 44,286. The firm’s fifty day simple moving average is $3.79 and its two-hundred day simple moving average is $5.64. The stock has a market cap of $9.14 million, a P/E ratio of -0.16 and a beta of 1.27. Biora Therapeutics has a 1 year low of $1.43 and a 1 year high of $19.90.

About Biora Therapeutics

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.